What is the role of medications in the treatment of familial Mediterranean fever (FMF)?

Updated: Apr 07, 2020
  • Author: John O Meyerhoff, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

The goals of therapy are to reduce morbidity and to prevent complications. Colchicine is the drug of choice; patients who do not respond to colchicine or cannot tolerate it may benefit from the addition or substitution of biologic agents that inhibit interleukin-1. Of those, canakinumab, anakinra, and rilonacept have demonstrated efficacy, but only canakinumab is approved for use in the United States.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!